23 November 2015 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S FDA approved Pradaxa (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis and pulmonary embolism in patients who have undergone hip replacement surgery.

For more details, go to: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/11-23-2015-fda-approves-pradaxa-dabigatran-etexilate-mesylate-prophylaxis-deep-venous-thrombosis-dvt-pulmonary-embolism-pe-hip-replacement-surgery.html